

**NEOPROBE 3<sup>rd</sup> QUARTER AND BUSINESS UPDATE CONFERENCE CALL INVITATION**  
**Conference Call Scheduled for 11:00 AM ET, Tuesday, November 3<sup>rd</sup>**

DUBLIN, OHIO – October 28, 2009 -- Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced it would report its financial results for the third quarter of 2009 on Monday, November 2, 2009 after the close of the financial markets. The Company has scheduled a conference call with the investment community to discuss the financial results for the following morning, Tuesday, November 3, 2009 at 11:00 AM ET.

During the conference call, Neoprobe's President and CEO, David Bupp, and Vice President and CFO, Brent Larson, will provide a business update and discuss the Company's results for the third quarter and first three quarters of 2009.

The conference call can be accessed as follows:

<b>Conference Call Information</b>			
<b>TO PARTICIPATE LIVE:</b>		<b>TO LISTEN TO A REPLAY:</b>	
Date:	Nov. 3, 2009	Available until:	Nov. 10, 2009
Time:	11:00 AM ET	Toll-free (U.S.) Dial in # :	877-660-6853
		International Dial in # :	201-612-7415
Toll-free (U.S.) Dial in # :	877-407-8033	Replay Passcodes:	
International Dial in # :	201-689-8033	Account #:	286
		Conference ID #:	336400

**About Neoprobe**

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe<sup>®</sup> GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek<sup>®</sup> and RIGScan<sup>®</sup> CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. [www.neoprobe.com](http://www.neoprobe.com)